Paul W H I Parren
Overview
Explore the profile of Paul W H I Parren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
9447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Murin C, Gunn B, Parren P, Kobinger G
Front Immunol
. 2022 Mar;
13:859919.
PMID: 35251051
No abstract available.
12.
van Kampen M, Kuipers-De Wilt L, van Egmond M, Reinders-Blankert P, van den Bremer E, Wang G, et al.
J Pharm Sci
. 2022 Mar;
111(6):1587-1598.
PMID: 35235843
The hexamerization of natural, human IgG antibodies after cell surface antigen binding can induce activation of the classical complement pathway. Mutations stimulating Fc domain-mediated hexamerization can potentiate complement activation and...
13.
Gruijs M, Braster R, Overdijk M, Hellingman T, Verploegen S, Korthouwer R, et al.
J Oncol
. 2022 Jan;
2022:3577928.
PMID: 35035479
Surgical resection of the tumor is the primary treatment of colorectal cancer patients. However, we previously demonstrated that abdominal surgery promotes the adherence of circulating tumor cells (CTC) in the...
14.
Zwarthoff S, Widmer K, Kuipers A, Strasser J, Ruyken M, Aerts P, et al.
Proc Natl Acad Sci U S A
. 2021 Jun;
118(26).
PMID: 34155115
Complement is an important effector mechanism for antibody-mediated clearance of infections and tumor cells. Upon binding to target cells, the antibody's constant (Fc) domain recruits complement component C1 to initiate...
15.
Neijssen J, Cardoso R, Chevalier K, Wiegman L, Valerius T, Anderson G, et al.
J Biol Chem
. 2021 Apr;
296:100641.
PMID: 33839159
A bispecific antibody (BsAb) targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) pathways represents a novel approach to overcome resistance to targeted therapies in patients with...
16.
Vergoossen D, Plomp J, Gstottner C, Fillie-Grijpma Y, Augustinus R, Verpalen R, et al.
Proc Natl Acad Sci U S A
. 2021 Mar;
118(13).
PMID: 33753489
Human immunoglobulin (Ig) G4 usually displays antiinflammatory activity, and observations of IgG4 autoantibodies causing severe autoimmune disorders are therefore poorly understood. In blood, IgG4 naturally engages in a stochastic process...
17.
de Weerdt I, Lameris R, Ruben J, de Boer R, Kloosterman J, King L, et al.
Clin Cancer Res
. 2021 Jan;
27(6):1744-1755.
PMID: 33451981
Purpose: Although considerable progress has been made with autologous T cell-based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well...
18.
de Weerdt I, Lameris R, Scheffer G, Vree J, de Boer R, Stam A, et al.
Cancer Immunol Res
. 2020 Nov;
9(1):50-61.
PMID: 33177109
Novel T cell-based therapies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), are thought to have strong potential. Progress, however, has been...
19.
Overdijk M, Strumane K, Beurskens F, Ortiz Buijsse A, Vermot-Desroches C, Vuillermoz B, et al.
Mol Cancer Ther
. 2020 Aug;
19(10):2126-2138.
PMID: 32847982
Higher-order death receptor 5 (DR5) clustering can induce tumor cell death; however, therapeutic compounds targeting DR5 have achieved limited clinical efficacy. We describe HexaBody-DR5/DR5, an equimolar mixture of two DR5-specific...
20.
Oostindie S, van der Horst H, Kil L, Strumane K, Overdijk M, van den Brink E, et al.
Blood Cancer J
. 2020 Apr;
10(3):30.
PMID: 32341336
Tetraspanin CD37 has recently received renewed interest as a therapeutic target for B-cell malignancies. Although complement-dependent cytotoxicity (CDC) is a powerful Fc-mediated effector function for killing hematological cancer cells, CD37-specific...